Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology

Aim To present our experience with sentinel lymph node biopsy (SLNB) performed in patients with multicentric breast cancer. Methods Between May 2001 and May 2004, 42 patients with multicentric breast cancer and a clinically negative axilla underwent lymphatic mapping either by a single subareolar (n=25) or a double peritumoral/subdermal injection (n=17) of 99Tc-HSA nanocolloids. The sentinel lymph node (SLN) was evaluated by intraoperative frozen section and axillary dissection was performed only in case of positive SLN. Results Mean age was 49 years (range 25–78). Mean number of SLNs identified by lymphoscintigraphy was 1.36 (range 1–5) and mean number of SLNs removed at surgery was 1.55 (range 1–5), with an identification rate of 100%. The mean number of hot spots identified by lymphoscintigraphy was similar in patients who underwent single or double injections (1.36 and 1.35, respectively). In 21 of 42 patients the SLN was positive, and in seven of these 21 patients the SLN was the only positive node. After a median follow-up of 24 months no overt axillary metastases occurred in patients with negative SLN. Conclusions The number of SLNs is not dependent on the number and site of injections. SLNB is our standard procedure for nodal staging in patients with multicentric breast cancer and a clinically negative axilla.